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A B S T R A C T
Hypophosphatasia is a metabolic bone disease characterized by bone and teeth hypomineralization due to defective
function of tissue-nonspecific alkaline phosphatase (TNSALP). The disorder is caused by various mutations in the
TNSALP gene localized on short arm of chromosome 1. Infantile hypophosphatasia is a severe form of the disease inher-
ited as an autosomal recessive trait which presents before age of six months and often has fatal outcome. We report a pa-
tient with typical clinical course for infantile hypophosphatasia who was homozygous for the c.1402G>A mutation. The
same mutation has been previously associated with a more severe perinatal form also in a Croatian family what indi-
cates a possible common ancestral origin and phenotypic variability potential of c.1402G>Amutation of TNSALP gene.
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Introduction
Hypophoshatasia (OMIM 146300, 241500, 241510) is
a rare inherited metabolic bone disease characterized by
bone hypomineralization and deficiency of tissue-non-
specific alkaline phosphatase1. According to severity and
age of onset five different forms of hypophosphatasia can
be distinguished: perinatal, infantile, childhood, adult
and odontohyphophosphatasia1. In some reports peri-
natal benign hypophosphatasia is classified as the sixth
clinical form2. The gene encoding TNSALP (ALPL gene)
is located in chromosome band 1p36.1-34, and consists of
12 exons comprising about 50kb3. So far, at least 209 dis-
tinctive mutations have been reported4. About 80% of
these mutations are missense mutations. Numerous rare
compound heterozygous genotypes make it difficult to
establish genotype-phenotype correlations. Severe forms
of the disease are perinatal and infantile hypophosphata-
sia, which are both associated with mutations mostly lo-
calized in regions coding crucial domains of the protein5.
Infantile hypophosphatasia usually presents before the
sixth month of life after a normal neonatal period with
failure to thrive, clinical manifestations of rickets, bone
ossification abnormalities, functional craniosynostosis,
hypercalcemia and hypercalcuria. Mortality is over 50%
in the first year of life and is mostly due to respiratory
failure and pneumonia which are pulmonary complica-
tions of their skeletal disease. However, prognosis im-
proves in individuals who survive infancy1.
Case Report
This girl was born as the second child of healthy and
unrelated parents. Her older brother is healthy.
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The infant was delivered at 36 weeks of gestation by
cesarean section due to premature rupture of fetal mem-
branes followed by weak labor. Birth weight was 2190 g
(between 3rd and 10th percentile), length was 44.5 cm
(10th percentile) and head circumference was 31.5 cm
(between 10th and 50th percentile). The infant had myo-
clonic convulsions in the fourth and twelfth hour of life
which were treated with intravenous administration of
phenobarbiton. Seizures recurred on the third and fourth
day of life and again respond well to therapeutic doses of
barbiturates. Diagnostic procedures revealed no abnor-
malities apart from old periventricular intracranial hem-
orrhage showed by brain ultrasound. The child was dis-
charged from the hospital with oral phenobarbiton ther-
apy on the 17th day of life. During the following months
she was unremarkable and without seizures until the
fourth month of life when she started to lose weight. At
the age of five months she presented with features of in-
fantile hypophosphatasia including failure to thrive, mild
psychomotor delay, hypotonia, wide cranial sutures, large
fontanel, micrognathia, asymmetric hypoplastic thorax
and widened wrists.
Laboratory results revealed severely decreased alka-
line phosphatase (4 U/L; reference range for infants
150–420 U/L) and hypercalcemia (3.28 mmol/L; refer-
ence range for infants. 2.3–2.8 mmol/L). Phosphate was
normal (1.73 mmol/L; reference range for infants 1.42–2.16
mmol/L) and PTH was suppressed (<0.2 pmol/L; refer-
ence range for adults 1–6 pmol/L) as expected. Increased
amount of phosphoetanolamine was found in serum (127
mmol/L; reference range 0–40 mmol/L) and urine (660
mmol/mol creatinine; reference range 0–25 mmol/mol
creatine). Bone turnover markers indicated increased
bone remodeling with high serum osteocalcin levels (>62
mg/L, normal values for infants 19.4 – 56.8 mg/L) but
normal b-CrossLaps in urine (1089 mg/mmol creatinine,
normal values for children <18 yrs 4089±2456 mg/mmol
creatinine). X-rays (Figure 1) and bone densitometry
showed severe bone hypomineralization (BMD in lumbal
region 0.119 g/cm2, Z-score –6.57 SD). All these findings
led to the clinical diagnosis of infantile hypophosphata-
sia. Mutation analysis by sequencing of the ALPL gene6
showed the homozygous missense mutation: c.1402G>A
(A451T).
Therapeutic efforts were aimed at normalizing blood
calcium and slowing down bone demineralization. A low
calcium diet decreased serum calcium and normocalce-
mia was established with calcitonine and chlorothiazide
therapy which was previously described to be successful7.
Subsequent radiographs showed some improvement in
bone mineralization but this could not be more thor-
oughly evaluated because the child died at the age of
eight months due to extensive bilateral pneumonia and
respiratory failure while waiting for bone marrow trans-
plantation.
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Fig. 1. Roentgenograms of the arms at the age of five months show
osteopenic bones with thinned cortices and irregular metapyses.
Ossification nuclei of carpal bones are undeveloped.
Fig. 2. Roentgenogram of the fetus with perinatal hypophospha-
tasia shows findings tipicall for hypophosphatasia. The overall
shape is much more preserved than the ossification. The upper
limbs show defective ossification of the left ulna and right radius
and ulna. The spine shows skipped ossification of the cervical
vertebrae and no ossification on the pedicles. The femurs are
slightly bowed, while the tibias are straight and of normal lenght.
The femurs, tibias and humeri show V-shaped metaphyseal de-
fects very typical of hypophosphatasia.
Discussion
We report a patient with classic infantile hypophos-
phatasia caused by a homozygous A451T mutation in the
TNSALP gene. This mutation was previously tested in at
least 50 unrelated normal individuals to ensure that the
base change was not a frequent polymorphism8. The resi-
due is close to the homodimer interface8,9. This is consis-
tent with previous reports showing that most mutations
associated with a severe phenotype affect residues local-
ized in crucial domains such as the catalytic site, ligand-
-binding site and homodimer interface5. Alkaline pho-
sphatases in Escherichia coli and humans show 25–30%
homology, with conserved residues at the active site and
the metal-binding domains9 which demonstrate the evo-
lutional importance of these domains in TNSALP. The
substitution of alanine at position 451 to threonine resi-
due would have a great impact on catalytic activity.
Alanin is nonpolar amino-acid with hydrocarbon side
chain and hydrophobic features, while threonine consists
a hydroxyl group in the side chain, which interacts stron-
gly with the water by forming of hydrogen bonds. Con-
version of alanin to threonine, could influence directly on
homodimer interactions or structural conformational con-
ditions. This mutation was for the first time described,
also in the homozygous form, in a severely deformed fe-
tus at the 24weeks of gestation8. Alkaline phosphatase in
fetal blood obtained by chordocentesis was low (12 IU/L).
Postmortem examination showed a poorly mineralized
skull and vertebrae and slightly bowed femurs (Figure
2). First child in that family was born as a stillborn with
hydrocephalus and tetraphocomelia at 36 weeks of gesta-
tion, but there was no evidence that it had hypophospha-
tasia. The parents originated from the same region of
Croatia as our patient’s family. To the best of our knowl-
edge this mutation was not described before in non-
-Croats, what indicates a possible common ancestral ori-
gin of the A451T mutation in Croatian population. Both
cases implicate the importance of this protein domain for
function of TNSALP. Allosteric features are determined,
among other factors, with a molecular structure of the
dimer interface. Because this enzyme is only active in
dimeric form, any mutation found in and around ho-
modimer interface is expected to severely compromise
the function of the TNSALP protein. Additionally, these
two different phenotypes in patients homozygous for the
same mutation confirm that modifying genetic or possi-
bly epigenetic factors could play an important role in
clinical expression10. Serum alkaline phosphatase activ-
ity in our patient was very low (4 IU/L), which is more of-
ten seen in perinatal than in infantile form. Zurutuza et
al. also described two families with same homozygous
mutation R433C in exon 12, but different forms of lethal
hypophosphatasia (infantile and perinatal) as in our case5.
The mutation is located in the long insertion loop. Identi-
fication of causative mutation has an important implica-
tion for prenatal diagnosis in eventual next pregnancies.
Like our patient, all other reported patients with in-
fantile hypophosphatasia and neonatal seizures had fatal
outcomes11, what confirms the thesis that seizures indi-
cate bad prognosis in patients with hypophosphatasia.
Another interesting fact about A451T mutation, that
further indicates its phenotypic potential and requires
additional research of modifying factors, is its possible
dominant negative effect12. In the family we report, both
parents and the brother of our patient are heterozygous
for A451T mutation. They all had reduced TNSALP se-
rum activity and no other clinical signs or symptoms of
the disease, which is more concordant with observation
that heterozygous carriers of severe forms are clinically
unaffected12. However, it is known that parents of pa-
tients carrying mutations with in vitro dominant nega-
tive effect may express only very mild symptoms (mostly
premature loss of teeth) or even may be completely
unaffected13,14.
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HIPOFOSFATAZIJA: FENOTIPSKA VARIJABILNOST I MOGU]E HRVATSKO PODRIJETLO
c.1402G>A MUTACIJE TNSALP GENA
S A @ E T A K
Hipofosfatazija je nasljedna metaboli~ka bolest kostiju koja nastaje zbog nedostatne funkcije tkivno nespecifi~ne al-
kaline fosfataze (TNSALP), a o~ituje se smanjenom mineralizacijom kostiju i zubi. Bolest nastaje zbog mutacija
TNSALP gena koji se nalazi na kratkom kraku 1. kromosoma. Infantilni oblik hipofosfatazije se naslje|uje autosomno
recesivno, a klini~ki se bolest o~ituje unutar prvih {est mjeseci `ivota i nerijetko ima fatalan ishod. Prikazujemo `ensko
dojen~e oboljelo od infantilne hipofosfatazije s klini~kom slikom karakteristi~nom za ovaj oblik bolesti, koje je bilo
homozigot za c.1402G>A mutaciju TNSALP gena. Ista mutacija je ranije opisana u fetusa koji je tako|er bio hrvatskog
porijekla, ali je imao te`i, perinatalni oblik bolesti. U ~lanku se raspravlja o mogu}em zajedni~kom porijeklu i feno-
tipskoj varijabilnosti mutacije c.1402G>A gena TNSALP.
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